Hydrogen gas inhalation randomized double blinded trial for ulcerative colitis

Hydrogen gas inhalation randomized double blinded trial for ulcerative colitis - Hydrogen gas inhalation randomized double blinded trial for ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042017

Enrollment

Registered

2020-10-05

Start date

2020-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

hydrogen gas 8 weeks inhalation the inhalation for 4 hours per day 12 weeks observation after the inhalation placebo gas 8 weeks inhalation the inhalation for 4 hours per day 12 weeks observatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ulcerative colitis eMayo score1, Mayo score3~10

Exclusion criteria

Exclusion criteria: All cases with liver disease, kidney disease, heart disease, or other serious complications. Lactating women, pregnant women, and all cases of possible pregnancy. Patients with respiratory diseases such as chronic obstructive respiratory disease and asthma.

Design outcomes

Primary

Measure	Time frame
The change of endoscopic findings and symptoms from the baseline to 8th week between hydrogen gas and placebo gas	—

Countries

Japan

Contacts

Public ContactDai Ishikawa

Juntendo University Hospital Gastroenterology

dai@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026